BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies

EBioMedicine

Jacobo Pardo-Seco¹  Camille Locht¹  Alex I. Kanno²  Carlos Martin³  Ana Isabel Dacosta³  Jesus Gonzalo-Asensio⁴  Esther Broset⁴  Irene Rivero-Calle⁵  Luciana C.C. Leite⁶  Nacho Aguilo⁶  Federico Martinón-Torres⁶ 

[1] CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain;Corresponding author.;GENVIP Research Group (www.genvip.org), Instituto de Investigación Sanitaria de Santiago (SERGAS), University of Santiago de Compostela, Galicia, Spain;Grupo de Genetica de Micobacterias, Departamento de Microbiología y Medicina Preventiva, Facultad de Medicina, Universidad de Zaragoza, IIS-Aragón, Zaragoza 50009, Spain;Laboratório de Desenvolvimento de Vacinas, Instituto Butantan, Av. Vital Brasil 1500, São Paulo 05503-900, Brazil;Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain;

关键词: Live-tuberculosis vaccines;    Heterologous immunity;    Non-specific effects;    DTP;    BCG;    MTBVAC;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: The Bacillus Calmette-Guérin (BCG), the only vaccine against tuberculosis (TB) currently in use, has shown beneficial effects against unrelated infections and to enhance immune responses to vaccines. However, there is little evidence regarding the influence of BCG vaccination on pertussis. Methods: Here, we studied the ability of BCG to improve the immune responses to diphtheria, tetanus, and acellular (DTaP) or whole-cell pertussis (DTwP) vaccination in a mouse model. We included MTBVAC, an experimental live-attenuated vaccine derived from Mycobacterium tuberculosis, in our studies to explore if it presents similar heterologous immunity as BCG. Furthermore, we explored the potential effect of routine BCG vaccination on pertussis incidence worldwide. Findings: We found that both BCG and MTBVAC when administered before DTaP, triggered Th1 immune responses against diphtheria, tetanus, and pertussis in mice. Immunization with DTaP alone failed to trigger a Th1 response, as measured by the production of IFN-γ. Humoral responses against DTaP antigens were also enhanced by previous immunization with BCG or MTBVAC. Furthermore, exploration of human epidemiological data showed that pertussis incidence was 10-fold lower in countries that use DTaP and BCG compared to countries that use only DTaP. Interpretation: BCG vaccination may have a beneficial impact on the protection against pertussis conferred by DTaP. Further randomized controlled trials are needed to properly define the impact of BCG on pertussis incidence in a controlled setting. This could be a major finding that would support changes in immunization policies. Funding: This work was supported by the Ministry of “Economía y Competitividad”; European Commission H2020 program, “Gobierno de Aragón”; CIBERES; “Fundação Butantan”; Instituto de Salud Carlos III and “Fondo FEDER”.

【 授权许可】

Unknown